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Abstract
Background: MYCN is amplified in small cell lung cancers and several pediatric tumors, including alveolar
rhabdomyosarcomas and neuroblastomas. MYCN protein is known to play a key oncogenic role in both alveolar
rhabdomyosarcomas and neuroblastomas. MYCN opposite strand (MYCNOS) is a gene located on the antisense
strand to MYCN that encodes alternatively spliced transcripts, two of which (MYCNOS-01 and MYCNOS-02) are
known to be expressed in neuroblastoma and small cell lung cancer with reciprocal regulation between MYCNOS-
02 and MYCN reported for neuroblastomas. We sought to determine a functional role for MYCNOS-01 in alveolar
rhabdomyosarcoma and neuroblastoma cells and identify any associated regulatory effects between MYCN and
MYCNOS-01.
Methods: MYCNOS-01, MYCNOS-02 and MYCN expression levels were assessed in alveolar rhabdomyosarcoma and
neuroblastoma cell lines and tumor samples from patients using Affymetrix microarray data and quantitative RT-
PCR. Following MYCNOS-01 or MYCN siRNA knockdown and MYCNOS-01 overexpression, transcript levels were
assayed by quantitative RT-PCR and MYCN protein expression assessed by Western blot and immunofluorescence.
Additionally, effects on cell growth, apoptosis and cell cycle profiles were determined by a metabolic assay, caspase
activity and flow cytometry, respectively.
Results: MYCNOS-01 transcript levels were generally higher in NB and RMS tumor samples and cell lines with MYCN
genomic amplification. RNA interference of MYCNOS-01 expression did not alter MYCN transcript levels but decreased
MYCN protein levels. Conversely, MYCN reduction increased MYCNOS-01 transcript levels, creating a negative feedback
loop on MYCN protein levels. Reduction of MYCNOS-01 or MYCN expression decreased cell growth in MYCN-amplified
alveolar rhabdomyosarcoma and neuroblastoma cell lines. This is consistent with MYCNOS-01-mediated regulation of
MYCN contributing to the phenotype observed.
Conclusions: An alternative transcript of MYCNOS, MYCNOS-01, post-transcriptionally regulates MYCN levels and affects
growth in MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
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Background
Several pediatric cancers feature amplification at the
chromosomal region 2p24 including alveolar rhabdo-
myosarcoma (ARMS), neuroblastoma (NB), medullo-
blastoma, Wilms’ tumor, and retinoblastoma [1–3]. The
minimum common region of amplification at 2p24 in
rhabdomyosarcoma (RMS) and NB has been found to
consistently include the oncogene MYCN and amplifica-
tion of MYCN is used clinically as a prognostic marker
in NB [3–7]. Amplification or overexpression of MYCN
leads to dysregulation of proliferation, differentiation
and the cell cycle in NB [8] and contributes to cell
growth in ARMS [9]. MYCN is also capable of positive
auto-regulation as well as auto-suppression in NB, po-
tentially fine-tuning MYCN levels [10–12]. In ARMS,
MYCN transcription is driven by PAX3-FOXO1, the
protein product of a fusion between the PAX3 and
FOXO1 genes that has prognostic significance in these
tumors [9, 13]. RMS and NB are a major cause of cancer
related death in children with a five-year survival rate of
around 50% for high-risk NB cases, including those with
MYCN amplification, and 40% for PAX3-FOXO1 positive
RMS cases [13, 14].
MYCN opposite-strand (MYCNOS, N-CYM, MYCN-
AS1, NYCM, CYMN) is produced by antisense transcrip-
tion across exon 1 and intron 1 of MYCN that has been
shown to be highly expressed in MYCN-amplified NB
and small cell lung cancer [15, 16]. Two alternative
transcripts denoted MYCNOS-01 and MYCNOS-02
(Additional file 1: Figure S1A) are fully sequence-verified
[15]. There is an emerging body of evidence for roles of
MYCNOS-02 through an encoded protein (NCYM) that
promotes NB tumorigenesis, in particular via its regula-
tion of MYCN expression, and also its role as a long
non-coding RNA (lncRNA) [17–22]. NCYM has been
shown to mediate expression of MYCN protein by both
direct interaction and also indirectly via inhibition of
GSK3β, leading to decreased MYCN phosphorylation
and a concomitant increase in MYCN protein stability
[17]. This was associated with increased tumor growth
and metastasis [17]. The same study also concluded that
MYCN positively drives the promoter of MYCNOS-02 in
an E-box-dependent manner [17]. As well as increasing
MYCN protein, NCYM has been found to increase
MYCN cleavage to produce the anti-apoptotic protein
Myc-nick in NB [22]. NCYM has also been shown to
promote aggressiveness in NB by increasing OCT4 ex-
pression via its stabilization of MYCN [20].
LncRNAs are commonly defined as transcripts of over
200 nucleotides in length that in general do not code for
a protein [23]. MYCNOS-02 lncRNA is able to regulate
the usage of two MYCN promoters and therefore ex-
pression of different MYCN transcripts via interaction
with binding partners such as G3BP1. This in turn
results in expression of different isoforms of the MYCN
protein [18]. MYCNOS-02 lncRNA has also been found
to recruit CTCF to the MYCN promoter to increase
recruitment of activating chromatin marks and thus
increase MYCN expression [19]. This positive regulation
of MYCN suppressed differentiation and increased
growth, invasion and metastasis in NB [19]. Additionally,
a recent study has shown MYCNOS-02 lncRNA can inter-
act with the RNA-binding protein NonO to indirectly in-
crease MYCN transcript levels post-transcriptionally [21].
Overall, these studies show that both the MYCNOS-02
encoded protein and lncRNA play a role in growth, inva-
sion and metastasis of NB cells [17, 19, 20].
Unlike MYCNOS-02, a functional role for the MYC-
NOS-01 transcript has not yet been investigated, despite
original annotation of its sequence being consistent with a
lncRNA [15]. In this study we therefore investigated the
role of MYCNOS-01 as a lncRNA in RMS and NB. We
demonstrate that MYCNOS-01 post-transcriptionally reg-
ulates MYCN protein levels without affecting MYCN
mRNA levels, whilst MYCN regulates MYCNOS-01 tran-
scription. We show that silencing of MYCNOS-01 in RMS
and NB cell lines with MYCN amplification reduces cell
viability, similar to the effects of MYCN reduction. Thus,
we conclude that regulation of MYCN by MYCNOS-01
contributes to the reduction in cell growth in RMS and
NB cell lines afterMYCNOS-01 silencing.
Methods
Translation and Kozak sequence prediction tools
Translation prediction for the MYCNOS-01 transcript
sequence was carried out using the ExPASy translate
tool (http://web.expasy.org/translate/) [24] and Kozak
sequence prediction was carried out using ATGpr
(http://atgpr.dbcls.jp/) [25].
Cell culture
Human ARMS cell line RMS-01 was available directly
from the authors [26] and the RH30 cell line was a gift
from Peter Houghton (St Jude Children’s Research
Hospital, Memphis, Tennessee). The human NB cell
lines KELLY and SY5Y were obtained from ECACC (cat.
No. 92110411) and ATCC (cat. No. CRL-2266) respect-
ively. RMS-01 and RH30 were cultured in DMEM
(Thermo Fisher Scientific, MA, USA) and KELLY and
SY5Y were cultured in RPMI-1640 medium (Thermo
Fisher Scientific, MA, USA) supplemented with 10%
Foetal Bovine Serum (FBS), 2 mM L-glutamine and 1%
penicillin/streptomycin. The MYCN overexpressing and
matched empty vector expressing RH30 lines were gen-
erated as previously described in Tonelli et al., (2012) [9]
and cultured in DMEM supplemented with 400 μg/ml
geneticin. Cells were maintained at 37 °C and 5% CO2.
Data from short tandem repeat testing of the cell lines
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using the GenePrint 10 system (Promega, WI, USA)
were compared with records for these cell lines in a re-
pository database or our own archival records. This was
consistent with the origin of these cell lines.
Analyses of expression profiling data
Data uploaded to R2 Genomics Analysis and Visualisa-
tion Platform (http://r2.amc.nl) were used for analyses.
These included 101 RMS samples (ITCC) [6], a set of 19
RMS cell lines (Versteeg) [27], 88 NB samples (Versteeg)
and 24 NB cell lines (Versteeg) that had been previously
profiled using the Affymetrix GeneChip with the HGU133
Plus2 array. Probe sets could distinguish MYCNOS-01
and MYCNOS-02 transcripts: probe set 216188_at detects
MYCNOS-01, set 207028_at detects MYCNOS-02 and set
209757_s_at was used to detectMYCN.
qRT-PCR
MYCNOS-01 and MYCNOS-02 expression data was
available from primary sample biopsies from RMS pa-
tients. Samples and details of RNA extraction were pre-
viously described [6, 28] with appropriate approvals for
investigation. RNA was isolated from cell lines using the
RNeasy mini kit (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions. Cell line cDNA was
synthesised using the High Capacity cDNA Reverse
Transcriptase kit (Applied Biosystems, CA, USA) and
patient sample cDNA was synthesised using SuperScript
II reverse transcriptase (Invitrogen, CA, USA) following
the manufacturers’ protocol. Samples were run for qRT-
PCR on the ViiA™ 7 Real-Time PCR System (Applied
Biosystems, CA, USA). The following Taqman® probe and
primer sets were used: MYCNOS-01 Hs01032821_m1,
MYCNOS-02 Hs01040745_m1, MYCN Hs_00232074_m1.
Human ACTB (Beta Actin) endogenous control (Applied
Biosystems, CA, USA) was used to normalise gene expres-
sion. Each sample was run in triplicate. Analysis of MYCN
expression and copy number in patient samples is
described in [6].
siRNA transfection
Oligonucleotides for specific silencing of MYCNOS-01,
MYCNOS-02 and MYCN were transfected into cells
using Lipofectamine RNAimax (Invitrogen, CA, USA)
according to the manufacturer’s instructions. All siRNAs
were obtained from GE Dharmacon (CO, USA). The
sequence from 5′ to 3′ for the three siRNAs against
MYCNOS-01 were as follows: siMYCNOS-01 1 GGGAC
AAGAGCACAGUUUCUU, siMYCNOS-01 2 GGUAAG
UUAAGGUACAGCCUU, siMYCNOS-01 3 GGAGUAU
UUGUUUAGUGCUUU. The sequences for the three
siRNAs against MYCNOS-02 were GAAAGAAGGGUA-
GUCCGAAUU for siMYCNOS-02 1, GACCGAUGCU
UCUAACCCAUU for siMYCNOS-02 2, CCGCUUUGA
CUGCGUGUUGUU for siMYCNOS-02 3. For knock-
down of MYCN a pool of three siRNAs was used with
sequences GAAGAAAUCGACGUGGUCA, CCAAGGC
UGUCACCACAUU, AAUUGAACACGCUCGGACU, as
previously described [9]. The control siRNA used was the
ON-TARGETplus non-targeting control pool (GE
Dharmacon, CO, USA). Samples were analyzed by qRT-
PCR, Western blot, flow cytometry or phenotypic assays
at time-points indicated in the relevant figures.
Western blotting
Protein lysates were prepared using Cell Lysis Buffer
(Cell Signaling Technology, MA, USA) and their con-
centration measured by the Pierce™ BCA protein assay
kit (Thermo Fisher Scientific, MA, USA). Protein sam-
ples were resolved by SDS-PAGE and transferred onto
PVDF membranes. Blots were incubated with the follow-
ing primary antibodies: MYCN SC-791 (1:200, Santa
Cruz, TX, USA), PARP 9542 (1:1000, Cell Signaling
Technology, MA, USA), Phospho-C-Myc (Thr58/Ser62)
04–217 (1:4000, Merck Millipore, MA, USA), GAPDH
MAB374 (1:10000, Merck Millipore, MA, USA). Blots
were then incubated with rabbit (sc-2313, Santa Cruz,
TX, USA) or mouse (A9044, Sigma-Aldrich, MO, USA)
horseradish peroxidase-conjugated secondary antibody di-
luted to 1:4000 depending on primary antibody species.
Blots were developed using the ECL™ Prime Western
Blotting System (GE Healthcare, IL, USA) on the Chemi-
doc Touch Imaging System (Bio-Rad, CA, USA). Densi-
tometry was performed using Bio-Rad Image Lab 5.2.1
(Bio-Rad, CA, USA).
Immunofluorescence staining
Cells cultured in chamber slides were fixed with 2%
paraformaldehyde for 15 min at room temperature and
permeabilised with 0.1% Triton X-100. Samples were
blocked in PBS with 10% goat serum and 1% BSA for
1 h. Samples were incubated with primary MYCN anti-
body SC-53993 (1:500, Santa Cruz, TX, USA) overnight
at 4 °C followed by secondary antibody Alexa Fluor 555
goat anti-mouse (1:400, Invitrogen, CA, USA) for
30 min at room temperature. Cells were counterstained
with DAPI. Fluorescent images were captured using a
Zeiss Axioplan 2 microscope (Oberkochen, Germany)
using a 16× objective and a standard exposure time opti-
mised for control treated cells. The sum of the intensity
for MYCN staining was measured using Image J soft-
ware and made relative to the number of cells in that
field of view, indicated by DAPI.
Plasmid production and transfection
Full-length MYCNOS-01 transcript (RefSeq NR_110230)
was cloned into the pcDNA5/TO vector (Invitrogen, CA,
USA) and the construct verified by Sanger sequencing
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(Eurofins Genomics, Ebersberg, Germany). For plasmid
transfection, Lipofectamine 2000 (Invitrogen, CA, USA)
was used following the manufacturer’s instructions. Sam-
ples were analyzed by qRT-PCR and Western blot at
time-points indicated in the relevant figures.
Proteasome inhibition
For protein stability experiments, cells were transfected
for a total of 48 h and treated for the final 4 h with ei-
ther 10 μM MG132 (Sigma-Aldrich, MO, USA) in
DMSO or DMSO control. Protein was then extracted
from cells for analysis by Western blot.
Cell viability assay
Cells were transfected as six repeats in a 96-well plate to
assess the effects of gene knockdown. Cell viability was
assessed by the MTS method using the CellTiter 96®
Aqueous One Solution Cell Proliferation Assay (Pro-
mega, WI, USA). Fresh media plus 20 μl assay reagent
were added at the indicated time-point. After 2.5 h incu-
bation at 37 °C and 5% CO2 the absorbance of each well
was measured at 492 nm on a FLUOstar Optima plate
reader (BMG Labtech, Ortenberg, Germany).
Apoptosis assay
Cells were transfected in quadruplicate in a 96-well plate
and apoptosis measured by evaluating the activation of
caspase 3/7 at the indicated time-point by replacement
of 50 μl of media with 50 μl of Caspase-Glo® 3/7 Assay
(Promega, WI, USA). After 1 h incubation protected
from light at room temperature, the samples were trans-
ferred to a white-walled 96-well plate and luminescence
of each well was read on a FLUOstar Optima plate
reader (BMG Labtech, Ortenberg, Germany). The cas-
pase signal intensity was normalised by the absorbance
measurement from the corresponding MTS assay.
Flow cytometry
Cells were fixed in 70% ethanol at -20 °C overnight,
washed with PBS and resuspended in 1 ml PBS contain-
ing 100 μg/ml RNase A and 40 μg/ml Propidium Iodide.
Samples were incubated for 30 min at 37 °C then ana-
lyzed on a BD™ LSRII Flow Cytometer (BD Biosciences,
CA, USA).
Statistical analysis
Graphs represent means ± standard deviation from mul-
tiple independent experiments as stated in figure leg-
ends. Statistical significance was measured by unpaired
two-tailed Student t-test or by one-way analysis of vari-
ance (ANOVA) with post hoc Dunnett’s test for multiple
comparisons. For linear correlation studies of gene ex-
pression Pearson’s coefficient (R) was calculated between
each pair of variables to indicate the strength of the
linear association. p < 0.05 was considered significant
and indicated by a single asterisk, p < 0.01 is indicated by
a double asterisk, and p < 0.001 is indicated by a triple
asterisk.
Results
MYCNOS-01 is predicted to be non-protein coding and
correlations between MYCNOS and MYCN transcript levels
in RMS and NB patients and cell lines
Previous data showed protein encoding potential for
MYCNOS-02 transcripts [15]. In contrast, translation
and Kozak sequence analysis for MYCNOS-01 predicted
transcripts to be non-protein coding since the probabil-
ity any start codon present in the MYCNOS-01 sequence
is an initiation codon is very low (Additional file 1:
Figure S1B and C). The relationship between MYCN
and MYCNOS-01 transcript levels was then investigated
by mining publically available expression profiling data
for RMS and NB samples from patients and cell lines. A
significant correlation between levels of MYCNOS-01
and MYCN expression and MYCNOS-02 and MYCN ex-
pression was identified considering all RMS samples
(Fig. 1a and b) and cell lines (Fig. 1c and d). There was
also a significant positive correlation between both
MYCNOS transcripts and MYCN transcript expression
in NB patient samples (Fig. 1e and f) and cell lines (Fig.
1g and h) that is consistent with the literature for MYC-
NOS-02 [17, 19]. For NB patient samples and cell lines,
levels of MYCNOS-01 and 02 were higher in cases with
MYCN amplification (Fig. 1e-h) versus cases without.
Amplification at 2p24 in RMS is also associated with
high MYCNOS-01 and MYCNOS-02 expression levels,
as indicated in data mined for the cell lines (Fig. 1c and
d) and qRT-PCR analyses of a limited number of cases
with known MYCN amplification status as well as the cell
lines (Additional file 2: Figure S2A–D). MYCN and MYC-
NOS-01 transcript levels in RMS and NB showed no
significant correlations when MYCN amplified cases were
excluded (RMS p = 0.72, R = 0.078; NB p = 0.42, R = 0.097).
MYCNOS-01 regulates MYCN protein but not transcript
levels in MYCN-amplified RMS and NB cells
To determine whether MYCNOS-01 regulates MYCN
transcript levels, which may be consistent with the cor-
relations in their expression levels in NB and RMS de-
rived samples, we performed siRNA-mediated silencing
of MYCNOS-01 in cell lines. RMS cell lines tested had
either high (RMS-01) or intermediate (RH30) MYCN ex-
pression levels, and NB cell lines used had high (KELLY)
and low (SY5Y) levels of MYCN [7–9]. The relative
MYCNOS and MYCN transcript levels for the four cell
lines used are indicated in Additional file 2: Figure S2E.
In high MYCN-expressing lines, no consistent effect
on MYCN transcript levels was observed after silencing
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of MYCNOS-01 for 72 h (Fig. 2a-d). To determine whether
MYCNOS-01 is regulating MYCN post-transcriptionally,
we also assessed MYCN protein levels by Western blotting.
MYCN protein was decreased in cells transfected with
MYCNOS-01 siRNAs compared to non-targeting control in
high MYCN-expressing cell lines RMS-01 and KELLY
(Fig. 2e, f ). This is supported by the decrease in MYCN
immunofluorescence signal after MYCNOS-01 depletion
compared to control in these cell lines (Additional file 3:
Figure S3A-F). Furthermore, MYCNOS-01 overexpression
a b
c d
e f
g h
Fig. 1 Correlation of MYCNOS transcripts and MYCN transcript expression in RMS and NB. a Correlation between MYCNOS-01 and MYCN measured
by Affymetrix microarray in 101 RMS patient samples (R = 0.501, p < 0.0001) and (b) correlation between MYCNOS-02 and MYCN in these patient
samples (R = 0.483, p < 0.0001). c Correlation between MYCNOS-01 and MYCN measured by Affymetrix microarray in 19 RMS cell lines (R = 0.523,
p = 0.022) and (d) correlation between MYCNOS-02 and MYCN (R = 0.672, p = 0.0016). e Correlation between MYCNOS-01 and MYCN measured by
Affymetrix microarray in 88 NB patient samples (R = 0.696, p < 0.0001) and (f) correlation between MYCNOS-02 and MYCN in these patient samples
(R = 0.759, p < 0.0001). g Correlation between MYCNOS-01 and MYCN measured by Affymetrix microarray in 24 NB cell lines (R = 0.782, p < 0.0001)
and (h) correlation between MYCNOS-02 and MYCN (R = 0.877, p < 0.0001). Data derived from R2 genomics analysis and visualisation platform.
MYCN-amplified cases or cell lines are depicted with circles
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has no effect on MYCN transcript levels but causes a
slight increase in MYCN protein; the effect observed is
limited since RMS-01 and KELLY cells express very high
basal levels of MYCN (Additional file 4: Figure S4). Exper-
iments on RMS-01 cells including a proteasome inhibitor
showed no increase in phosphorylated MYCN with MYC-
NOS-01 knockdown, indicating that MYCN protein
stability was not affected (Additional file 5: Figure S5).
However, MYCNOS-01 silencing had no strong effect on
eitherMYCN transcript or protein levels in the ARMS cell
line RH30 with intermediate MYCN expression (Fig. 3a-
c). Due to the low expression levels of MYCN protein in
the NB cell line SY5Y, no bands were visible by Western
blot but there was similarly no MYCNOS-01-mediated
effect on MYCN transcript expression (Fig. 3d and e).
As a role for MYCNOS-02 in RMS has not been previ-
ously evaluated, we also performed siRNA-mediated si-
lencing of MYCNOS-02 to determine the effects on
MYCN mRNA and protein expression in RMS-01 and
KELLY cells (Additional file 6: Figure S6). Similar levels
of MYCNOS-02 silencing were observed with all 3 siR-
NAs, but there was no consistent effect on MYCN
expression at the RNA or protein level.
Overall, these results demonstrate that MYCNOS-01
reduces MYCN protein levels in MYCN-amplified RMS
and NB cell lines but not through altering MYCN
phosphorylation.
MYCN regulates MYCNOS-01 transcript levels
Silencing MYCN in RMS and NB caused a significant
increase in MYCNOS-01 expression in both high
MYCN-expressing (RMS-01, KELLY) and intermediate
MYCN-expressing (RH30) RMS and NB cell lines
(Fig. 4a-i). Conversely, overexpressing MYCN in RH30
decreased MYCNOS-01 expression (Fig. 4j-l). MYCN
was found to similarly regulate MYCNOS-02 in RMS
and NB with MYCN amplification (Additional file 7:
Figure S7). Overall, these results indicate MYCN nega-
tively regulates MYCNOS-01 expression whilst MYC-
NOS-01 positively regulates MYCN protein levels.
Decreasing MYCNOS-01 levels results in decreased cell
viability in MYCN-amplified RMS and NB cells
We next investigated the phenotypic effects of MYCNOS-
01 and MYCNOS-02 depletion on RMS (RMS-01, RH30)
and NB (KELLY, SY5Y) cells. Decreasing MYCNOS-01 ex-
pression resulted in a significant decrease in cell viability
compared to negative control with all MYCNOS-01 siR-
NAs inMYCN-amplified RMS-01 and KELLYcells (Fig. 5a
and b), similar to the reduction in cell viability that is seen
a
e f
b c d
Fig. 2 MYCN transcript and protein expression after MYCNOS-01 knockdown in high MYCN-expressing RMS and NB. qRT-PCR detecting MYCNOS-
01 transcript level after MYCNOS-01 knockdown for 72 h with three siRNAs in (a) RMS-01 and (c) KELLY. Corresponding MYCN transcript level
shown in (b) RMS-01 and (d) KELLY. Expression relative to NT control. (e) and (f) MYCN protein levels after MYCNOS-01 knockdown for 72 h and
96 h with three siRNAs in RMS-01 and KELLY respectively. GAPDH used as loading control. Densitometry values shown above each blot normalised to
GAPDH and relative to NT control. Data representative of three repeats. NT = non-targeting control. Relative expression of transcripts in these cell lines
are indicated in Additional file 2: Figure S2E
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with siRNA-mediated MYCN silencing (Fig. 5a and b). Si-
lencing MYCNOS-01 did not reduce MYCN protein lower
than directMYCN silencing (Fig. 5c), but showed a similar
or greater effect on RMS cell viability (Fig. 5a) raising the
possibility that MYCNOS-01 may have targets in addition
to MYCN in RMS. Decreasing MYCNOS-02 expression
also significantly decreased cell viability in these cell lines
(Additional file 8: Figure S8A and B). In contrast, silencing
of MYCNOS-01 did not significantly affect cell viability in
intermediate (RH30) and low (SY5Y) MYCN expressing
cells overall (Fig. 6a and b). However, although the effect
was less for RH30 compared to RMS-01, MYCN knock-
down did significantly decrease cell growth as we have
previously reported [9] (Fig. 6a). MYCN reduction in
SY5Y had no effect, although levels of MYCN are very low
(Fig. 6b). There was no significant increase in caspase 3/7
activation or PARP cleavage in MYCNOS-01 or MYCN
siRNA treated cells compared to non-targeting control in-
dicating apoptosis was not induced (Additional file 9:
Figure S9). However, MYCNOS-02 knockdown promoted
apoptosis in RMS-01 and KELLY cells (Additional file 10:
Figure S10). Decreasing MYCNOS-01 expression had no
effect on cell cycle progression but silencing MYCN
caused a G1 arrest in both RMS-01 and KELLY
(Additional file 11: Figure S11). Based on all our results,
we propose a feedback model for MYCNOS-01 and
MYCN regulation in RMS and NB (Fig. 7).
Discussion
In this study, we have shown thatMYCNOS-01 andMYC-
NOS-02 can play important roles in RMS as well as NB
cell growth, at least in part via their regulation of MYCN.
Roles for MYCNOS-01 in RMS and NB and MYCNOS-02
in RMS have not been previously explored whilst our data
for the effect of MYCNOS-02 on growth of NB cells is
consistent with previous findings [17–22]. Regulation of
MYCN by MYCNOS-01 and MYCNOS-02 was readily ap-
parent in MYCN-amplified RMS and NB, which express
these transcripts at high levels, presumably as a result of
their co-amplification at the genomic level. In contrast, ef-
fects of MYCNOS transcripts on MYCN protein levels in
RMS and NB without high level MYCN amplification
were either less marked or not seen. The positive regula-
tion of MYCN by MYCNOS-01 and MYCNOS-02 likely
contribute to the cell growth of RMS and NB. This is
consistent with the phenotypic dose dependent effects and
dependencies of RMS and NB cells on MYCN levels seen
in this and previous studies [9, 29, 30].
a b d
c
e
Fig. 3 MYCN transcript and protein expression after MYCNOS-01 knockdown in intermediate and low MYCN-expressing RMS and NB. qRT-PCR
detecting MYCNOS-01 transcript level after MYCNOS-01 knockdown for 72 h with three siRNAs in (a) RH30 and (d) SY5Y. Corresponding MYCN
transcript level shown in (b) RH30 and (e) SY5Y. Expression relative to NT control. (c) MYCN protein levels after MYCNOS-01 knockdown for 72 h
and 96 h with three siRNAs in RH30. GAPDH used as loading control. Densitometry values shown above each blot normalised to GAPDH and
relative to NT control. Data representative of three repeats. NT = non-targeting control. Relative expression of transcripts in these cell lines are
indicated in Additional file 2: Figure S2E
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In addition to the positive regulation of MYCN by
MYCNOS-01, MYCN also negatively regulates MYCNOS-
01 transcription, summarized in Fig. 7. As MYCN protein
has been found to be recruited to its own intron 1 [10], in
line with the transcription start site for MYCNOS-01 on
the opposite strand, this binding activity could be involved
in MYCN-mediated regulation of MYCNOS-01. Previous
studies have also identified indirect MYCN negative feed-
back mechanisms involving trans-acting factors [12]. This
is likely a mechanism that fine-tunes MYCN expression
levels.
An increasing number of lncRNAs have now been
characterized and many have been linked to cancer pro-
gression [31]. Here we have shown that MYCNOS-01
can act as a cis-antisense lncRNA on its sense partner
MYCN. Although MYCN transcript expression was not
regulated by MYCNOS-01, we have identified a post-
transcriptional role for this lncRNA in regulating MYCN
a b c
d e f
g h i
j k l
Fig. 4 Effect of MYCN knockdown on MYCNOS-01 transcript expression in RMS and NB. a qRT-PCR and (b) Western blot for MYCN, and (c) qRT-
PCR for MYCNOS-01 after treatment with three pooled MYCN siRNAs for 72 h in RMS-01. d-f in KELLY as for (a)-(c). g-i in RH30 as for (a)-(c). j qRT-
PCR and (k) Western bot for MYCN, and (l) qRT-PCR for MYCNOS-01 in RH30 stably transfected with empty vector (EV) or HA-MYCN expressing
vector. Graphs and Western blots representative of three repeats. NT = non-targeting control
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protein levels. This is consistent with the lack of correl-
ation we found between the two transcripts in non-
amplified lines.
There are several examples of lncRNAs that regulate
protein partners post-transcriptionally without affecting
transcript expression [32–35]. For example, the lncRNA
PVT1 has been shown to be required for increasing
MYC protein stability and high expression levels in
8q24-amplified cancers [32]. In our study, we found no
evidence that MYCNOS-01 altered the stability of
MYCN protein via Thr58/Ser62 phosphorylation. An-
other example of post-transcriptional regulation is the
lncRNA treRNA, which has been shown to play a role in
tumor invasion and metastasis in breast cancer, and
which regulates the translation of E-cadherin mRNA in
these cells via redistribution of CDH1 to low molecular
weight polysomes to suppress translation [34]. Poten-
tially MYCNOS-01 could have a similar mechanism to
regulate translation efficiency of MYCN and thus its
protein expression. In addition, the lncRNA BACE1-AS
regulates translation of BACE1 by masking the binding
site for miR-485-5p, thus preventing miRNA-induced
translational repression and mRNA decay [35]. Another
possibility therefore is that MYCNOS-01 interacts with
an miRNA that targets MYCN for degradation, therefore
increasing MYCN protein expression by sequestering
a b
c d
Fig. 5 Knockdown of MYCNOS-01 inhibits cell viability in high MYCN-expressing RMS and NB. (ai) MTS assay showing cell viability of RMS-01 up to
144 h after transfection with three MYCNOS-01 siRNAs or three pooled MYCN siRNAs relative to NT siRNA. (bi) KELLY as in (ai). Corresponding qRT-
PCR for MYCNOS-01 (ii) and MYCN (iii) at 24 h shown below line graph. c MYCN protein levels after MYCNOS-01 or MYCN knockdown for 72 h in
RMS-01 and (d) in KELLY. Densitometry values shown above each blot normalised to GAPDH and relative to NT control. Data representative of
three repeats. Statistical analysis relative to non-targeting control. NT = non-targeting
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away a negative regulating factor. The above examples
indicate possible post-transcriptional mechanisms that
could be explored for MYCNOS-01-mediated regulation
of MYCN. Further investigations are required to deter-
mine molecular interactions with MYCNOS-01 and how
these regulate MYCN protein levels.
BothMYCNOS-01 andMYCNOS-02 shown in this study
in RMS and NB, and MYCNOS-02 shown previously in
NB, regulate MYCN protein levels [17, 19, 20]. However,
data on whether MYCNOS-02 is able to regulate MYCN at
the transcriptional level is conflicting. One report for
MYCNOS-02 indicates silencing of MYCNOS-02 does not
affect MYCN expression at the transcriptional level [17].
However, other studies suggest that MYCNOS-02 can
affect MYCN transcript expression in NB [18, 19, 21].
MYCNOS-02 has been found to interact with CTCF to
affect chromatin remodeling at theMYCN promoter there-
fore MYCN transcript expression [19]. However, in silico
a b
Fig. 6 Knockdown of MYCNOS-01 does not inhibit cell viability in intermediate or low MYCN-expressing RMS and NB. (ai) MTS assay showing cell
viability of RH30 up to 96 h after transfection with three MYCNOS-01 siRNAs or three pooled MYCN siRNAs relative to NT siRNA. (bi) SY5Y as in (ai).
Corresponding qRT-PCR for MYCNOS-01 (ii) and MYCN (iii) at 24 h shown below line graph. Data representative of three repeats. Statistical analysis
relative to non-targeting control. NT = non-targeting
Fig. 7 Schematic of proposed model for regulation between MYCN and MYCNOS-01. MYCN and MYCNOS-01 expression are both driven by
genomic amplification, although MYCN is expressed at higher levels than MYCNOS-01. MYCNOS-01 positively regulates MYCN protein levels and
MYCN negatively regulates MYCNOS-01 transcript levels as a form of negative feedback on MYCN. MYCNOS-01-mediated regulation of MYCN has
effects on cell viability but there is also likely a MYCN-independent signaling pathway
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prediction techniques suggest CTCF interacts with a re-
gion of MYCNOS-02 that does not overlap with the se-
quence of MYCNOS-01, supporting the possibility that
the two transcripts could have different binding partners
that are involved in MYCN regulation. It is possible for
two overlapping lncRNAs from the same locus to have
different characteristics and function. For example, the
CCAT1 locus encodes CCAT1-L that is located in the nu-
cleus and positively regulates MYC transcription and
CCAT1-S that is mainly located in the cytoplasm with no
effect on MYC transcript levels [36–38].
Previous studies of MYCNOS-02 have identified its role
in NB tumor growth and metastasis. In vitro, MYCNOS-
02 can suppress differentiation and promote metastasis,
invasion and cell proliferation partially due to its indirect
regulation of MYCN [19]. Our study found MYCNOS-01
also plays a role in MYCN-amplified RMS and NB cell
viability, although no effect was seen on cell cycle progres-
sion. Often a decrease in proliferation occurs with con-
comitant cell cycle arrest, however it is possible for these
two effects to be separated. For example, one study found
decreasing the tumor suppressors RPL5 or RPL11 resulted
in a reduction in ribosome content and translation cap-
acity, causing cells to progress at a lower rate through all
stages of the cell cycle thus resulting in decreased prolifer-
ation without cell cycle arrest [39].
MYCNOS-01 was also found to play a role in cell
growth via regulation of MYCN; silencing of MYCNOS-01
resulted in a reduction in MYCN protein levels. However,
MYCNOS-01 knockdown did produce a slightly different
phenotype to MYCN knockdown due to differences in
MYCN protein levels achieved. We have previously identified
that using different molecular tools to diminish MYCN can
affect the strength of phenotype detected depending on the
magnitude and endurance of MYCN reduction [9]. MYC-
NOS-01 knockdown did not decrease MYCN protein suffi-
ciently to produce a G1 arrest, in contrast to direct MYCN
knockdown. However, MYCNOS-01 reduction affecting
other protein targets and signaling pathways that contribute
to the phenotype observed cannot be excluded. Further de-
fining how MYCNOS-01 regulates MYCN, and possibly
other proteins, may lead to new approaches to perturb the
clinically aggressive phenotype of RMS and NB tumors.
Conclusions
MYCNOS-01 can be added to the growing list of lncRNAs
involved in tumorigenesis;MYCNOS-01 positively regulates
MYCN and MYCN negatively regulates MYCNOS-01, po-
tentially to fine-tune MYCN protein levels. MYCNOS-01
affects cell growth of MYCN-amplified RMS and NB and
could also play a role in other MYCN-driven cancers. Al-
though directly targeting lncRNAs and MYCN is challen-
ging, future therapeutic strategies could disrupt specific
lncRNA-protein interactions to reduce MYCN levels.
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Expression relative to normal cells. (PDF 50 kb)
Additional file 3: Figure S3. Effect of MYCNOS-01 knockdown on MYCN
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Quantification of MYCN staining intensity from (A) relative to total number
of cells and normalised to non-targeting control. (C) qRT-PCR detecting
MYCNOS-01 transcript level matching experiment shown in (A). (D)-(F) in
KELLY as for (A)-(C). Data representative of three repeats. Statistical analysis
relative to non-targeting control. NT = non-targeting. (PDF 74664 kb)
Additional file 4: Figure S4. Effect of MYCNOS-01 overexpression on
MYCN transcript and protein expression. qRT-PCR detecting MYCNOS-01
transcript level after 72 h transient transfection with two MYCNOS-01
overexpressing vectors or empty vector control in (A) RMS-01 and (D)
KELLY. Corresponding MYCN transcript level shown in (B) RMS-01 and (E)
KELLY. Expression relative to empty vector control. MYCN protein levels
after MYCNOS-01 overexpression for 72 h shown in (C) RMS-01 and (F)
KELLY. GAPDH used as loading control. Densitometry values shown
above each blot normalised to GAPDH and relative to empty vector
control. EV = empty vector. (PDF 3518 kb)
Additional file 5: Figure S5. Effect of MYCNOS-01 knockdown on MYCN
protein stability. (A) RMS-01 cells treated with three MYCNOS-01 siRNAs
for 48 h including 4 h treatment with DMSO or MG132. Densitometry
values shown above each blot normalised to GAPDH and relative to NT control
for each condition. Blots representative of experiments run in triplicate. (B) MYC-
NOS-01 transcript expression after MYCNOS-01 knockdown for 24 h measured
by qRT-PCR. NT = non-targeting control. (PDF 584 kb)
Additional file 6: Figure S6. Effect of MYCNOS-02 knockdown on MYCN
transcript and protein expression in RMS and NB. qRT-PCR detecting MYC-
NOS-02 transcript level after MYCNOS-02 knockdown with three siRNAs in
(A) RMS-01 and (D) KELLY. Corresponding MYCN transcript level shown in
(B) RMS-01 and (E) KELLY. Expression relative to NT control. Western blots
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siRNAs shown in (C) RMS-01 and (F) KELLY. GAPDH used as loading
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GAPDH and relative to NT control. Data representative of 3 repeats. NT =
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are indicated in Additional file 2: Figure S2E. (PDF 3709 kb)
Additional file 7: Figure S7. Effect of MYCN knockdown on MYCNOS-02
transcript expression in RMS and NB. (A) qRT-PCR and (B) Western blot for
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as in (Ai). Corresponding qRT-PCR of MYCNOS-02 (ii) at 24 h shown below
line graph. Data representative of two repeats. Statistical analysis relative
to non-targeting control. NT = non-targeting. (PDF 82 kb)
Additional file 9: Figure S9. Knockdown of MYCNOS-01 does not induce
apoptosis. (A) Caspase 3/7 signalling intensity in RMS-01 after transfection
with three MYCNOS-01 siRNAs or three pooled MYCN siRNAs for 96 h relative
to cell viability and normalised to NT siRNA. (B) Western blot of total and
cleaved PARP in RMS-01 after transfection with three MYCNOS-01 siRNAs or
three pooled MYCN siRNAs. (C, D) in KELLY, (E, F) in RH30 and (G, H) in SY5Y
as for (A, B). Data representative of three repeats. NT = non-targeting, tPARP
= total PARP, cPARP = cleaved PARP. (PDF 5703 kb)
Additional file 10: Figure S10. Knockdown of MYCNOS-02 does induce
apoptosis. (A) Caspase 3/7 signalling intensity in RMS-01 after transfection
with three MYCNOS-02 siRNAs for 96 h relative to cell viability and normalised
to NT siRNA. (B) Western blot of total and cleaved PARP in RMS-01 after
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representative of two repeats. NT = non-targeting, tPARP = total PARP,
cPARP = cleaved PARP. (PDF 3672 kb)
Additional file 11: Figure S11. Knockdown of MYCNOS-01 does not
affect cell cycle progression. (A) Flow cytometry 96 h post-transfection
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